VEGF-mediated Immunosuppression
Cross-source consensus on VEGF-mediated Immunosuppression from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Highlighted claims
- VEGF has both angiogenic and immunosuppressive effects. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- VEGF can impair dendritic cell maturation, reduce tumour T-cell infiltration, and increase suppressive immune cell populations. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The INDUCE strategy hypothesizes that VEGF-associated immunosuppressive resistance limits immune-mediated antitumour efficacy. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- High VEGF levels in liver metastases are considered capable of promoting immunosuppression through suppressive immune cells. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- VEGF inhibition may normalize tumour vasculature and reduce immunosuppressive features of the tumour microenvironment. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)